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Antibiotic-resistant bacterial pathogens threaten public health. Because many anti-biotics target
specific bacterial enzymes or reactions, corresponding genes may mutate under selection and lead
to antibiotic resistance. Accordingly, antimicrobials that selectively target overall microbial cell
integrity may offer alternative approaches to therapeutic design. Naturally occurring mammalian
α- and θ-defensins are potent, non-toxic microbicides that may be useful for treating infections by
antibiotic-resistant pathogens, because certain defensin peptides disrupt bacterial but not
mammalian cell membranes. To test this concept, clinical isolates of methicillin-resistant
Staphylococcus aureus (MRSA), including vancomycin heteroresistant strains, and ciprofloxacinresistant Pseudomonas aeruginosa (CipR-PA) were tested for sensitivity to α-defensins Crp-4,
RMAD-4, and HNPs 1–3, and to RTD-1, a macaque θ-defensin-1. In vitro, 3 µM Crp-4, RMAD-4,
and RTD-1 reduced MRSA cell survival by 99%, regardless of vancomycin susceptibility. For PA
clinical isolates that differ in fluoroquinolone resistance and virulence phenotype, peptide efficacy
was independent of strain ciprofloxacin resistance, site of isolation, or virulence factor expression.
Thus, Crp-4, RMAD-4, and RTD-1 are effective in vitro antimicrobials against clinical isolates of
MRSA and CipR-PA, perhaps providing templates for development of α- and θ-defensin-based
microbicides against antibiotic resistant or virulent infectious agents.
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The economic costs of antimicrobial resistant infections has reached nearly $30 billion
dollars per year in the US1. In 2002, of health care–associated infections that resulted in
99,000 deaths, approximately 16% were reported to the CDC as resistant to antibiotics2–5.
The increase in antibiotic resistance narrows the options for the treatment of infections
caused by multidrug-resistant bacteria5, 6.
The Gram-negative bacterium Pseudomonas aeruginosa (PA) is a leading cause of
nosocomial infections for which the fluoroquinolone antibiotics, e.g. ciprofloxacin, are
commonly prescribed. Over the past decade, the prevalence of ciprofloxacin-resistant (CipR)
PA strains has increased 3-fold in parallel to the trend of prescribing this antibiotic class7.
Upwards of 30% of clinical PA strains are multidrug-resistant, and some are resistant to all
available antibiotics5, 8–10. In addition, PA strains have an arsenal of virulence factors,
including a type III secretion system (TTSS) that induces cytotoxicity and expression of
ExoU or ExoS effector proteins which are virulence factors that influence disease severity
by phagocyte evasion during acute infections11.

NIH-PA Author Manuscript

Methicillin-resistant Staphylococcus aureus (MRSA) are Gram-positive bacteria with
resistance to all β-lactam compounds except one, accounting for nearly 60% of all clinical
isolates from ICU patients12. Limited to the healthcare setting in the past, new, more
virulent MRSA strains have emerged in the community, and they are now responsible for
infections across both the community and healthcare settings. In addition, MRSA strains
increasingly have developed varying degrees of resistance to vancomycin, the accepted
treatment standard13, and hospital-associated health care costs for patients with MRSArelated infections are nearly double those of patients with methicillin-sensitive S. aureus14.
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Multi-drug resistant PA and MRSA are treated with antibiotics that target specific bacterial
reactions or enzymes to inhibit cell replication, cell wall biosynthesis, or they may kill
bacteria directly. Antibiotic exposure enables bacteria to acquire resistance through
mutations that allow for target drug degradation, reduced drug affinity to target sites, altered
metabolic pathways, and/or reduced drug accumulation15–17. For example, ciprofloxacin
inhibits bacterial replication by inhibiting DNA gyrase and topoisomerase IV, thereby
blocking bacterial cell division18. CipR PA acquire mutations to DNA gyrase and or
topoisomerase to escape its lethal antibiotic effects and by active removal of ciprofloxacin
via broad substrate efflux pumps to expel the drug and prevent its accumulation within
cells17. On the other hand, vancomycin inhibits bacterial cell wall biosynthesis by binding to
the C-terminal D-Ala-D-Ala of pentapeptide peptidoglycan precursors to block
transpeptidation19. Heteroresistance to vancomycin in MRSA reportedly results from
repeated vancomycin exposure selecting for a thickened cell wall that blocks vancomycin
from its target site20, and this resistant phenotype has accounted in part for persistence of
bacteremia and increased mortality21, 22. One approach to facilitate the treatment of antibiotic-resistant infections may be to combine current therapies with broad-spectrum peptide
microbicides that kill bacteria by general, independent mechanisms such as membrane
disruption.
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Mammalian defensins are 2–5 kDa, broad spectrum, cationic antimicrobial peptides, with
structures that are defined by specific tridisulfide arrays23. The α-, β-, and θ- defensins
compose the mammalian defensin family, and each subfamily differs with respect to
structural features that are imposed by specific disulfide connectivities, and they have
distinct primary sites of expression24. For example, the α-defensin tridisulfide array is
characterized by conserved CI–VI, CII–IV, CIII–V cysteine pairings, and β-defensins are
characterized by a CI–V, CII–IV, CIII–VI disulfide connectivity25. α-Defensin genes are
expressed by promyelocytes mainly accumulate in neutrophil azurophil granules, and those
expressed by Paneth cells are secreted into the small intestinal lumen. Certain β-defensins,
on the other hand, are expressed widely by epithelia at diverse mucosal barrier
interfaces26, 27. θ-Defensins are the only macrocyclic peptides known in the animal kingdom
and are expressed in the bone marrow of only Old World monkeys. The peptides derive
from truncated α-defensin genes, assemble from two hemi-precursors, and contain a
tridisulfide array that is arranged in the form of a parallel ladder28.
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The mechanisms of defensin microbicidal activity have been investigated extensively29.
Based on in vitro studies, micromolar levels of α-defensins may disrupt microbial
membranes selectively by inducing either stable or transient defects of variable size in
model membranes composed of microbial phospholipids30, 31. Induction of membrane
defects leads to target cell permeabilization, K+ efflux, depolarization, dissipation of
electrochemical gradients, leakage, and eventual cell death32–35. Analyses of defensinbilayer in5 teractions by small angle X-ray scatter, showed that mouse Paneth cell αdefensin cryptdin-4 (Crp-4), rhesus myeloid α-defensin RMAD-4, and the rhesus θ-defensin
RTD-1 induce negative Gaussian, or saddle splay, curvature to create pores in model
membranes and facilitating membrane disruption36. On the other hand, at lower peptide
concentrations defensins can also inhibit bacterial peptidoglycan synthesis by lipid II
binding37, 38, and defensins may use a lipid II binding mechanism to exert antimicrobial
effects.
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Because α-, and θ-defensins kill bacteria by these general mechanisms, which differ from
those of ciprofloxacin and vancomycin, we reasoned that vancomycin-heteroresistant
MRSA and CipR PA may be susceptible to the microbicidal effects of exposure to these
defensin peptides. To test this hypothesis, the survival of clinical isolates of
vancomycinheteroresistant MRSA and CipR PA exposed to Crp4, RMAD-4, RTD-1, and
human neutrophil α-defensins HNPs 1–3 were determined. Under the conditions of the in
vitro bactericidal assays, nearly all MRSA and PA strains were sensitive to all peptides
except for HNPs, irrespective of antibiotic resistance. In addition, PA sensitivity to αdefensins was not related to site of isolation, degree of ciprofloxacin resistance, TTSS
effector genotype, or cytotoxic potential. Because Crp-4, RMAD-4, and RTD-1 are nonhemolytic, resistant to proteolytic degradation, and among the most potent known defensins,
they may offer promise for development of novel antimicrobial therapeutics.
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Peptide Preparation
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Peptides (Figure 1) were purified to homogeneity by reverse phase high performance liquid
chromatography (RP-HPLC), and their identities were confirmed by MALDI-TOF MS and
by acid-urea polyacrylamide gel electrophoresis (AU-PAGE) as described39, 40.
Recombinant Crp-4 and RMAD-4 peptides were expressed in Escherichia coli as N-terminal
His6-tagged fusion proteins using the pET28a expression system (Novagen, Inc. Madison,
WI)32, 41, 42. Crp-4 and RMAD-4 templates were cloned in pCR-2.1 TOPO, verified by
DNA sequencing, subcloned into pET28a plasmid DNA (Novagen, Inc., Madison, WI), and
transformed into E. coli BL21(DE3)-CodonPlus-RIL cells (Stratagene) for recombinant
expression32, 41. His6-tagged Crp-4 fusion peptides were purified using nickel-nitrilotriacetic
acid (Ni-NTA, Qiagen) resin affinity chromatography43. After CNBr cleavage of the His6
tag, peptides were purified by sequential C18 reverse-phase high performance liquid
chromatography (RP-HPLC), and molecular masses of purified peptides were determined
using MALDI-TOF MS on a Bruker Microflex LRF (Bruker, Fremont, CA). Solution
structures of recombinant peptides prepared by this approach have been determined by
NMR44, 45.
Human neutrophil peptides (HNPs) were isolated from samples enriched in neutrophils
granules prepared from peripheral blood leukocytes46, 47. Briefly, after removing platelets
from human blood by centrifugation at 200 × g for 10 min and hypotonic lysis of red blood
cells, the leukocyte-enriched cell fraction was resuspended in 0.34 M sucrose, pH 7.4,
homogenized, and cellular debris deposited by centrifugation at 200 × g for 10 min, leaving
a granule-rich supernatant. Granules deposited by 30 min centrifugation at 27,000 × g at 4°C
were extracted for 18 h at 4°C with 10% acetic acid, and protein extracts were clarified by
centrifugation at 27,000 × g for 30 min at 4°C. A mixture of natural HNPs 1–3 was purified
by gel permeation chromatography using BioGel P10 (Bio-Rad Laboratories, Hercules, CA).
HNP-2 was purified further from pooled HNPs 1–3 by C18 RP-HPLC.
RTD-1 was synthesized as previously reported48. Synthetic RTD-1 is structurally and
biologically indistinguishable from peptide isolated from rhesus monkey neutrophils28.

NIH-PA Author Manuscript

Clinical Isolates
Bacterial isolates were grown from culture specimens obtained from hospitalized patients at
Huntington Hospital, Pasadena, CA as part of a longitudinal epidemiologic surveillance
study of resistant pathogens at the institution and were stored at −80°C until testing. All data
were analyzed anonymously. Susceptibility of MRSA isolates to vancomycin was
determined by Etest-based method according to manufacturer’s instructions (bio- Meriéux,
Durham, NC). Specifically, vancomycin heteroresistant phenotype was determined using the
Etest Glycopeptide Resistance Detection (GRD) method49. PA susceptibility to
ciprofloxacin was performed by broth microdilution method as recommended by the
Clinical Laboratory Standards Institute, with ciprofloxacin resistance defined by mini7 mum
inhibitory concentration of 2 µg/ml or greater. As for PA strains, genes encoding the TTSS
effector proteins ExoU and ExoS were assayed by polymerase chain reaction as before50. In
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vitro experiments were performed to determine PA cytotoxicity by infecting A549 lung
epithelial cells at a multiplicity of infection (MOI) of 10 and measuring LDH release at 3 h
post-infection using the CytoTox96 assay kit (Promega, Madison, WI).
MRSA bloodstream isolates and PA strains that caused pneumonia, as well as bacteremia,
wound and urinary tract infections were selected for this study to represent clinical isolates
that exhibit varying degrees of resistance to vancomycin (MRSA) and ciprofloxacin (PA),
respectively. The MRSA cohort included strains that caused persistent blood-stream
infection and different molecular epidemiologic characteristics; PA strains included those
with different virulence potential based on TTSS effector genotype and the rate and extent
of cytotoxicity observed in A549 cells. Two additional reference MRSA strains with
heteroresistance (Mu3) and intermediate resistance (Mu50) to vancomycin also were
studied.
In vitro Bactericidal Assays
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The α- and θ-defensins were tested for bactericidal activity against clinical isolates of
MRSA and PA in in vitro cell suspension assays32, 41. Bacteria grown to midexponential
phase in trypticase soy broth were deposited by centrifugation at 10,000 × g for 3 min, and
washed 3 times with 10 mM piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), pH 7.4,
supplemented with 1% (vol/vol) of trypticase soy broth (10 mM PIPES-TSB, pH 7.4). In
triplicate, 1–5 × 106 bacterial colony forming units (CFU)/ml were exposed to peptides in 50
µl 10 mM PIPES-TSB in 96-well polystyrene plates. Samples were incubated at 37°C with
shaking for 1 h, diluted 1:100 in 10 mM PIPES (pH 7.4), and plated on TSB agar plates
using an Autoplate 4000 (Spiral Biotech Inc., Bethesda, MD). Bacterial cell survival as a
function of peptide exposure was determined by counting CFU after overnight growth at
37°C. In these assays, after 1 h of peptide exposure replicate peptide-bacterial mixtures are
plated with a plating stylus onto the agar plate surface. The assay enables bacteria that are
not exposed or affected by peptide exposure to be enumerated, rather than produce lawns
that cannot be counted. On the other hand, sample dilution limits the lower end of the assay,
i.e., when >99.9% of exposed bacteria die. Because of the dilution factors involved, plates
on which no CFU were detected after overnight incubation actually may have had between 1
to 999 viable CFU in the peptide-bacterial mixture before dilution and plating. Accordingly,
the limit of detection is ≤ 103 CFU/ml, when no CFU are detected, and the ordinates of
bacterial survival curves are labeled in that manner.

NIH-PA Author Manuscript

RESULTS
Defensin sensitivity of vancomycin-heteroresistant MRSA strains
MRSA clinical isolates with varied resistance to vancomycin were exposed to Crp-4,
RMAD-4, and RTD-1 to determine their sensitivities to the peptides. Against standard
laboratory strains of S. aureus, Crp-4, RMAD-4, and RTD-1 are potent microbicides,
reducing cell viability 1000-fold at low micromolar peptide concentrations51, 52. Here,
Crp-4, RMAD-4, and RTD-1 similarly reduced viability of vancomycin-intermediate S.
aureus (VISA) control strain Mu50 and heteroresistant VISA (hVISA) control strain Mu3
with MBC values between 1.5 and 3 µM peptide (Table 1, Figs. 2A and B). Clinical isolates

Innate Immun. Author manuscript; available in PMC 2015 January 01.

Tai et al.

Page 6

NIH-PA Author Manuscript

characterized as hVISA by the Etest GRD method (Materials and Methods) were highly
sensitive to all defensins tested (Figs. 2C and D), with RMAD-4 had the greatest bactericidal
activity against every VISA/hVISA strain tested with 1.5 µM MBC values for all strains
(Table 1, Figs. 2A–D).
The potent microbicidal effects of Crp-4, RMAD-4, and RTD-1 against VI-SA/hVISA
control strains prompted us to test whether MRSA that had persisted in bacteremic patients
after extensive vancomycin treatment would be sensitive to these defensins. Clinical blood
isolates of MRSA that were not cleared by vancomycin treatment were assessed for survival
after Crp-4, RMAD-4, and RTD-1 exposure in vitro, and all MRSA clinical isolates were
sensitive to Crp-4, RMAD-4, and RTD-1 a peptide concentration dependent manner,
regardless of response to vancomycin treatment (Table 1, Figs. 3A–F). For example, the
MBC for RMAD-4 was 1.5 µM against vancomycin resistant and sensitive MRSA strains
(Table 1, Fig. 3), and no association existed between antibiotic resistance and defensin
susceptibility. Also, vancomycin-heteroresistant MRSA isolated from bacteremic patients
that failed to resolve with antibiotic therapy were susceptible to the three defensins and as
sensitive as culture adapted S. aureus strains (Table 1).

NIH-PA Author Manuscript

Sensitivity of ciprofloxacin-resistant PA to defensins
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PA develops resistance to ciprofloxacin by mutations in DNA gyrase, topoisomerase IV or
both and via efflux pumps that remove the drug and prevent its accumulation. Because the
α-defensins in this study are membrane disruptive microbicides and peptide accumulation
within target cells is not required for activity, we tested whether CipR PA are sensitive to
Crp-4 and RMAD-4. Bactericidal assays against ciprofloxacin-sensitive (CipS) and CipR PA
isolated from patient sputum showed that most PA sputum isolates were sensitive to both
Crp-4 and RMAD-4 at low micromolar peptide levels, regardless of antibiotic resistance
(Table 2, Fig. 4, See Supplementary Figure S1). In contrast to the variability of the relative
activities of Crp-4 and RMAD-4 against MRSA (Table 1, Fig. 3), Crp-4 consistently was
more active than RMAD-4 against most PA strains isolated from sputum (Table 2, Fig. 4).
Also, sputum isolates displayed more variability than MRSA strains regarding susceptibility
to Crp-4 and RMAD-4. Consistent with the defensin sensitivities of vancomycinheteroresistant MRSA strains, Crp-4 and RMAD-4 were bactericidal against PA sputum
isolates irrespective of strain ciprofloxacin resistance, there being no association between
PA isolate sensitivities to Crp-4 or RMAD-4 and antibiotic resistance.
The activities of defensins against PA sputum isolates were tested further by determining the
in vitro bactericidal effects of RTD-1, a mixture of natural HNPs 1–3, and purified HNP-2
against sputum PA isolates. RTD-1 at <1.5–6 µM reduced survival of the majority of sputum
PA isolates to ≤ 103 CFU/ml, below the limit of detection for these assays (Fig. 5). In
contrast, HNP 1–3 (Fig. 4A–C) and HNP-2 (Fig. 4D–F) did not affect survival of PA
sputum isolates, even at peptide concentrations 10–fold greater than levels at which Crp-4
and RTD-1 are highly microbicidal. Thus, HNPs, endogenous α-defensins that occur at
elevated serum concentrations during septicemia and certain infections in humans53, lacked
bactericidal activity against CipR and CipS PA strains under these in vitro conditions.
Although HNPs lacked activity against PA strains, they have been shown to have alternative
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innate host defense roles, including neutralization of anthrax lethal toxin and as
chemoattractants54, 55. Because PA isolates were sensitive to Crp-4 and RMAD-4
irrespective of antibiotic resistance, we focused on characterizing the activities of those
molecules rather than optimizing the activities of HNPs. Perhaps, the non-human peptides,
Crp-4, RMAD-4, and RTD-1, may offer promise as adjunct therapies for treatment of
bacterial infections that fail to resolve with conventional treatment.
PA sensitivity to α-defensins is independent of the site of isolation
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Major sites of PA infections include the urinary tract, lungs of cystic fibrosis patients, and
burn wounds, and PA strains may differ phenotypically, depending on the site of infection56.
Accordingly, bactericidal peptide assays were performed against PA clinical isolates from
patient urine (Fig. 6A, B, C, See Supplementary Figure S2), burn wounds (Fig. 6D, E, F, See
Supplementary Figure S3), and blood (Fig. 6G, H, I) to test their sensitivities to Crp-4 and
RMAD-4. Crp-4 was highly bactericidal against almost every PA isolate, irrespective of the
site of strain isolation. When exposed to ≥ 6 µM Crp4, no PA survivors were detected on
plates, i.e., ≤ 103 CFU/ml survived peptide exposure (Figure 6). RMAD-4 had similar
activities against PA wound isolates, but PA strains from blood and urine were more
variable in RMAD-4 susceptibility (Table 3). Therefore, little relation exists between the site
of PA strain isolation and resistance to these α-defensins.
ExoU or ExoS PA genotype and cytotoxicity do not induce α-defensin resistance

NIH-PA Author Manuscript

Most wild-type PA strains harbor the exoS gene encoding the TTSS effector protein, and
CipR PA populations are enriched for the exoU gene that codes for a TTSS effector protein,
which contributes to virulence in acute infection50, 57. Notably, ExoU expressing PA are
more virulent than ExoS strains in a murine model of acute pneumonia, and they cause more
severe disease in humans11, 58. To test whether these PA virulence geno-types have
differential α-defensin sensitivities, we performed bactericidal assays and determined
whether ExoU or ExoS genotype and α-defensin resistance are related a significantly by
constructing contingency tables and performing a Fisher’s exact test. We also grouped the
PA strains on the basis of the rate and extent of their cytotoxic effects on exposed A549 lung
epithelial cells, and we compared strain α-defensin susceptibility to cytotoxic potential. For
this purpose, PA sputum isolates were categorized as α-defensin resistant if less than 99%
killing occurred when exposed to 6 µM peptide. A subset of ExoU PA strains were resistant
to Crp-4 and RMAD-4 by this definition (Fig. 7), but no significant association existed
between genotype and α-defensin resistance (p>>0.1). Reduced sensitivity to Crp-4 or
RMAD-4, therefore, was not determined by TTSS effector genotype. Similarly, Crp4 and
RMAD-4 bactericidal activities against sputum isolates were independent of PA cytotoxic
potential, because highly cytotoxic strains (05038 and ML172) or non-cytotoxic strains
(06161 and ML75) were equally peptide sensitive (Fig. 7). Collectively, these studies show
that the bactericidal activities of Crp-4 and RMAD-4 against PA clinical isolates are
independent of CipR status, site of isolation, TTSS effector genotype, and cytotoxic
potential.
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Antimicrobial peptides have been proposed as templates for developing new therapeutics to
combat multidrug resistant pathogens59, 60, yet the efficacy of α-defensins against antibiotic
resistant clinical isolates has not been investigated extensively. Because general mechanisms
of α-defensin microbicidal action differ from most antibiotics, they may be useful in
combating infections by synergizing in combination with current antibiotic therapies.
Because Crp-4, RMAD-4, and RTD-1 resist proteolysis and are non-cytotoxic, potent
microbicides in vitro, they may provide new peptide-based platforms for antibiotic
development39, 61. To test the hypothesis that Crp-4, RMAD-4, and RTD-1 may be
efficacious against clinically important bacteria that also are antibiotic resistant, we assayed
the bactericidal activities of these defensins against isolates of MRSA with varying
resistance to vancomycin and CipR-PA. Under the in vitro assay conditions, Crp-4,
RMAD-4, and RTD-1 were highly active against MRSA and exhibited differential activities
against PA, irrespective of antibiotic resistance.
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The continuing emergence of MRSA strains with vancomycin resistance, the treatment
standard, underscores the need for new therapeutics. Against all strains of MRSA tested,
Crp-4, RMAD-4, and RTD-1 were highly active with MBC values of 1.5–3 µM peptide,
regardless of vancomycin resistance. In addition, RMAD-4 had a low MBC of 1.5 µM
peptide, the lowest concentration assayed, against all but one MRSA strain. The αdefensins investigated have microbicidal mechanisms of action that that disrupt cellular
integrity62. For example, certain defensins kill bacteria by sequestering lipid II and
inhibiting bacterial cell wall biosynthesis37, 63, 64, HNPs 1–3 mediate non-oxidative
microbial cell killing by sequential permeabilization of the outer and inner membranes and
formation of stable pores65, and Crp-4, RMAD-4, and RTD-1 disrupt membranes by
forming transient pores by induction of saddle-splay curvature66. At concentrations
approximately 10-fold greater than the MBC values reported here, Crp4 induces rapid efflux
of potassium ions from bacterial cells, a sensitive indicator of membrane disruption and cell
death67–6934, 70. We do not discount inhibition of cell wall biosynthesis as contributing to
the defensin mechanism of action in certain settings. On the other hand, over the one-hour
course of peptide exposure in the experiments we have presented, membrane disruption is
the most likely mechanism of action36, 71, a mechanism that differs from beta lactam
inhibitors and vancomycin. Thus, in combination with antibiotics, these defensin peptides
could synergize with current antibiotics to improve treatment of MRSA-related infections.
Gram-negative bacteria account for more than 30% of US hospital infections and are the
predominant ICU infections72–74. For example, PA is a leading cause of pneumonia, urinary
tract, and bloodstream infections72, and the incidence of multidrug resistant PA is rising75.
Crp-4, RMAD-4, RTD-1, and HNP 1–3 were tested against PA strains characterized by their
ciprofloxacin resistance, site of isolation, TTSS effector genotype and cytotoxic potential to
determine whether these traits correlated with defensin resistance. Under the conditions of
the in vitro assays, PA strains exhibited variable sensitivity to the defensin peptides tested
(Tables 2, 3), but defensin sensitivity was not associated with either of the phenotypic
characteristics. Cationic charge contributes to defensin bactericidal activity, but even though
Crp-4 and RMAD-4 are equally electropositive, Crp-4 was more active against PA strains
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but RMAD-4 was more potent against MRSA (Tables 1–3). Perhaps, the differential
bactericidal effects are due to differences in the surface charge or hydrophobicity
distribution of the two α-defensin peptides51. Although PA isolates from lung, blood, and
urine differ phenotypically56, the strains tested were equally sensitive to Crp-4 and
RMAD-4, irrespective of their site of isolation.
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The α-defensin and θ-defensin peptides tested hold promise toward the eventual
development of new therapeutic agents against the growing number of antibiotic resistant
pathogens. Although Crp-4, RMAD-4, and RTD-1 are highly active against many of the PA
strains tested in vitro, activity against PA strains may be diminished in the setting of chronic
lung infections where biofilm formation is induced76, 77, in that biofilm production enhances
resistance to bactericidal peptides. Whether biofilms diminish the activities of peptides
tested here is unknown78. Also, the ionic strength of assay media inhibits bactericidal
activities of Crp4 and RMAD-4, and binding of Crp-4, RMAD-4, and RTD-1 peptides to
plasma proteins has not been studied and may limit efficacy in vivo. Against bacteria that are
sensitive to these peptides, e.g., MBC ≤1.5 µM, bactericidal effects of Crp-4 and RMAD-4
are partially inhibited by 50 mM NaCl and completely inhibited at 100 mM NaCl. Thus, the
inherent salt sensitivity of these native molecules may limit therapeutic application of native,
full-length α-defensins, but reiterative selection of salt-insensitive variants of these peptides
could lead to drug development based on these peptide scaffolds. In contrast to the αdefensins, however, cyclized RTD-1 is as active in 150 mM NaCl as in low salt
media28, 48, 52, an indication that the θ-defensins may provide a more robust platform for
therapeutic development. Also, the disulfide array protects the Crp-4 and RMAD-4 from
proteolytic degradation, and α-defensins can be recovered from the protease- rich
environment of the mouse small and large bowel61, 79. Biophysical studies of Crp-4,
RMAD-4, and RTD-1 have established amino acid criteria necessary for their selective
membrane disruptive activities29, and Crp-4 and RMAD-4 are non-cytotoxic and
nonhemolytic at peptide concentrations as high as 100 µg/ml (data not shown)52.
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In addition to their broad spectrum in vitro microbicidal activities, rhesus θ- defensins 1–5
(RTDs 1–5), RTD-1 in particular, reduced the levels of TNF-α, IL-1α, IL- 1β, IL-6, and
IL-8 released by mixed blood leukocytes and THP-1 monocytes stimulated by bacteria or
LPS, respectively80. Also, systemic administration of RTD-1 to BALB/c mice was non-toxic
and stable in serum and plasma, and intravenous delivery of 5 mg/kg RTD-1 significantly
improved survival of BALB/c mice with E. coli peritonitis and cecal ligation-and-punctureinduced polymicrobial sepsis80. In contrast to HNPs, which are proinflammatory81–85, Crp4
and RMAD4 also inhibit cytokine and TNF-α release in the same in vitro assays, although
both are less inhibitory than RTD-1 (Kamdar et al., submitted for publication). Thus, new
antimicrobials that are developed to optimize both defensin-based bactericidal and
immunomodulatory properties may prove to be efficacious in combination with current
antibiotic therapies against antibiotic resistant bacteria while promoting survival from
systemic infections.
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Figure 1. Primary structures of α- and θ-defensins
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The primary structures of peptides investigated are aligned; net overall charge is shown at
right. α-Defensins are aligned by their conserved Cys residues (in bold), and their CI-CVI,
CII-CIV, and CIII-CV disulfide connectivities are depicted by brackets. The α-defensins from
mouse Paneth cells and rhesus neutrophils are highly cationic as compared to the human
myeloid peptides, HNPs 1–3. The octadecapeptide RTD-1, a θ-defensin, is a macrocyclic
peptide identified in rhesus macaque neutrophils and found only in Old World monkeys.
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Figure 2. Sensitivity of control MRSA strains to RMAD-4, Crp-4, and RTD-1 is independent of
antibiotic resistance
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Bactericidal peptide assays were performed in triplicate as described (see Materials and
Methods). Briefly, MRSA strains were exposed to peptides for 1 h, and surviving bacteria
were counted as CFU/ml at each peptide concentration (see Materials and Methods). Values
≤ 1 × 103 CFU/ml signify that no colonies were detected on plates after overnight growth.
Strain Mu50 (A) is a vancomycin-intermediate S. aureus (VISA) control, and Mu3 (B),
DH290 (C), and DH280 (D) are classified as heteroresistant VISA (hVISA) strains. Each
condition was performed in triplicate, with error bars denoting standard deviations from the
mean. Symbols: Crp-4 (-●-), RMAD-4 (-○-), and RTD-1 (-▼-).
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Figure 3. MRSA sensitivity to RMAD-4, Crp-4 and RTD-1 is not associated with antibiotic
resistance

Bactericidal peptide assays were performed in triplicate as described (Fig 2, Materials and
Methods). Strains EB151 (A), EB123 (B) and EB135 (C) are clinical isolates from patients
whose infections were cleared by vancomycin administration, in contrast to strains JJ593
(D), EB77 (E) and EB378 (F) which were isolated from persistent infections after failure of
treatment with vancomycin. All MRSA strains were sensitive to the defensins tested at low
micromolar concentrations (Table 1). Each condition was performed in triplicate with error
bars denoting standard deviation from the mean. Symbols: Crp-4 (-●-), RMAD-4 (-○-), and
RTD-1 (-▼-)
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Figure 4. Activities of Crp-4 and RMAD-4 against CipR and CipS strains of PA

Bactericidal peptide assays were performed in triplicate against clinical isolates from patient
sputum. Isolates 06397 (A), ML43 (B), and 06324 (C) are CipR-PA, and isolates 05080 (D),
06161 (E), and ML172 (F) are CipS-PA. No correlation exists between antibiotic resistance
and α-defensin activity (Table 2). Bars denote standard deviations from the mean. Symbols:
Crp-4 (-●-) and RMAD-4 (-○-).
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Figure 5. Attenuated activities of HNPs against PA clinical isolates

Survival of CipS P. aeruginosa strains 06397 (A), ML43 (B), and ML121 (C) and CipR–PA
strains 06161 (D), 05038 (E), and ML172 (F) isolated from patient sputum was measured
after exposure to Crp-4, RTD-1, and HNPs. In contrast to Crp-4 and RTD-1, 60 µM HNPs
had little bactericidal effects against P. aeruginosa, irrespective of CipR. RTD-1 and HNPs
assays were performed in triplicate, Crp-4 activity, assayed once at each peptide
concentration, was consistent with Fig. 3 Error bars denote standard deviations from the
mean.
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Figure 6. α-Defensin sensitivity is independent of the site of PA isolation
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P. aeruginosa strains WB 25 (A), WB 36 (B), WB 34 (C) isolated from the urine of patients,
strains WB 12 (D), WB 35 (E), and WB 44 (F) isolated from patient wounds, and WB 42
(G), WB 16 (H), and WB 15 (I) isolated from patient blood were exposed to 1.5–6 µM
peptides (Table 3). Assays were performed in triplicate; error bars denote standard deviation
from the mean. Symbols: Crp-4 (-●-) and RMAD-4 (-○-).
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Figure 7. Crp-4 or RMAD-4 bactericidal activity against PA are independent of ExoU or ExoS
genotype and cytotoxic potential

PA sputum isolates, characterized as ExoU (Black) or ExoS (white) are arranged in order of
increasing bacterial survival following exposure to 6 µM of Crp-4 or RMAD-4. Cytotoxic
potentials of each strain are also indicated by asterisks. PA strains were considered resistant
if > 1% of bacteria survived α-defensin peptide exposure. TTSS effector genotypes and
defensin resistance are not associated (p>0.1), and bactericidal activities were independent
of PA cytotoxic potential.
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Defensin MBC Values against VISA and hVISA MRSA Strains
MBC Value (µM)
MRSA Strain

Crp-4

RMAD-4

RTD-1

Mu50 (VISA)

3

1.5

3

Mu3 (hVISA)

1.5

3

1.5

DH 290 (hVISA)

3

1.5

3

DH280 (hVISA)

3

1.5

1.5

EB151§

1.5

1.5

1.5

EB123§

3

1.5

3

EB135§

3

1.5

3

JJ593‡

1.5

1.5

1.5

EB77‡

3

1.5

3

EB378‡

3

1.5

3
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§

Infection cleared by vancomycin administration.

‡

Persistent infection with vancomycin administration.
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α-Defensin MBC Values against CipR and CipS strains of Pseudomonas aeruginosa
P. aeruginosa strain

MBC Value (µM)
Crp-4

RMAD-4

1.5

3

ML43 (CipS)

1.5

1.5

06324 (CipS)

1.5

1.5

05080 (CipR)§

1.5

1.5

06161 (CipR)

1.5

1.5

1.5

1.5

06397

(CipS)†

ML172

(CipR)

†

CipS denotes ciprofloxacin-resistant strains;

§

CipR denotes ciprofloxacin-resistant strains.
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Table 3

NIH-PA Author Manuscript

α-Defensin MBC Values against P. aeruginosa Blood, Urine, and Wound Isolates
P. aeruginosa strain

MBC Value (µM)
Crp-4

RMAD-4

WB 25 (U)†

3

6

WB 36 (U)

1.5

6

WB 34 (U)

1.5

>6

WB 12 (W)‡

1.5

3

WB 35 (W)

1.5

3

WB 44 (W)

1.5

3

WB 42 (B)

1.5

1.5

WB 16 (B)

1.5

1.5

WB 15 (B)

1.5

1.5

Symbols denote anatomic source of the clinical isolates:
†

Urine,

NIH-PA Author Manuscript

‡

Wounds,

§

Blood.
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